CTLA4 and cancer: Immune checkpoint inhibitors (ICIs) (such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death-1 (PD-1), and PD-L1 inhibitors) have emerged as important strategies for various cancers (10, 11).